Recombinant or purified protein vaccines consist of protein antigens that have either been produced in a heterologous expression system (e.g., bacteria or yeast) or purified from large amounts of the pathogenic organism. The vaccinated person produces antibodies to the protein antigen, thus protecting him/her from disease.
Recombinant/purified protein vaccines are based on the concept that humoral immune responses mounted to an infection are often targeted toward specific localized regions on the surface of protein antigens known as epitopes. The recombinant proteins for vaccination are produced by expressing these immunogenic proteins using heterologous expression systems. The immunogenic protein antigens can also be purified from the infectious organism. Once purified, protein antigens, recombinant and endogenous, are administered with an adjuvant to boost the immune response. Administering just the most immunogenic protein or proteins from an infectious organisms as a vaccine produces a more targeted immune response. This strategy also eliminates the risk of active infection that can occur with live attenuated vaccines or even inactivated vaccines where inactivation is incomplete.
This report elaborates the market size, market characteristics, and market growth of the Recombinant Vaccines industry, and breaks down according to the type, application, and consumption area of Recombinant Vaccines. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Recombinant Vaccines in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.
Key players in the global Recombinant Vaccines market covered in Chapter 13:
Merck & Co., Inc
Protein Science Corporation
Johnson & Johnson
Mitsubishi Tanabe Pharma Corporation
Green Cross Corporation
Sanofi Pasteur SA
Serum Institute of India Pvt. Ltd
Emergent Bio Solutions, Inc.
In Chapter 6, on the basis of types, the Recombinant Vaccines market from 2015 to 2025 is primarily split into:
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines
In Chapter 7, on the basis of applications, the Recombinant Vaccines market from 2015 to 2025 covers:
Recombinant Human Vaccines
Animal Recombinant Vaccines
Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
Europe (Covered in Chapter 9)
Asia-Pacific (Covered in Chapter 10)
Middle East and Africa (Covered in Chapter 11)
South America (Covered in Chapter 12)
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025